Karyopharm Therapeutics (KPTI) Cost of Revenue (2019 - 2025)

Karyopharm Therapeutics has reported Cost of Revenue for 6 years, with the latest figure at $1.3 million in Q4 2025.

• For the quarter ending Q4 2025, Cost of Revenue rose 0.83% year-over-year to $1.3 million; the trailing twelve-month figure through Dec 2025 stood at $5.7 million (down 4.22% YoY), and the FY2025 full-year result was $5.8 million, down 3.33% from the prior year.
• Cost of Revenue for Q4 2025 stood at $1.3 million, down from $2.1 million in the prior quarter.
• The five-year high for Cost of Revenue was $2.1 million in Q3 2025, with the low at $589000.0 in Q3 2021.
• Historically, Cost of Revenue has averaged $1.3 million across 5 years, with a median of $1.3 million in 2024.
• Annual changes were most pronounced in 2022 — Cost of Revenue jumped 151.75% — and 2025, when it sank 34.33%.
• Karyopharm Therapeutics' Cost of Revenue stood at $742000.0 in 2021, then jumped by 151.75% to $1.9 million in 2022, then retreated by 20.45% to $1.5 million in 2023, then fell by 10.43% to $1.3 million in 2024, then advanced by 0.83% to $1.3 million in 2025.
• The last three Cost of Revenue figures came in at $1.3 million (Q4 2025), $2.1 million (Q3 2025), and $1.0 million (Q2 2025), per Business Quant data.